aop: Adverse Outcome Pathway Analysis

Provides tools for analyzing adverse outcome pathways (AOPs) for pharmacological and toxicological research. Functionality includes the ability to perform causal network analysis of networks developed in and exported from Cytoscape or existing as R graph objects, and identifying the point of departure/screening/risk value from concentration- response data.

AuthorLyle D. Burgoon <Lyle.D.Burgoon@usace.army.mil>
Date of publication2016-12-05 18:28:47
MaintainerLyle D. Burgoon <Lyle.D.Burgoon@usace.army.mil>
LicenseCC0
Version1.0.0

View on CRAN

Files in this package

aop
aop/inst
aop/inst/NEWS
aop/inst/extdata
aop/inst/extdata/steatosis_aop.png
aop/inst/extdata/steatosis_aop_json.cyjs
aop/inst/doc
aop/inst/doc/aop.Rmd
aop/inst/doc/concentration-response_analysis.R
aop/inst/doc/aop.R
aop/inst/doc/concentration-response_analysis.html
aop/inst/doc/aop.html
aop/inst/doc/concentration-response_analysis.Rmd
aop/inst/unitTests
aop/inst/unitTests/test_functions.R
aop/tests
aop/tests/runTests.R
aop/NAMESPACE
aop/data
aop/data/oxybenzone.rda
aop/R
aop/R/pod_analysis.R aop/R/aop_graph_analysis.R aop/R/aopCytoscape_Class.R aop/R/bmr_Class.R aop/R/aop_cytoscape_methods.R
aop/vignettes
aop/vignettes/aop.Rmd
aop/vignettes/concentration-response_analysis.Rmd
aop/README.md
aop/MD5
aop/build
aop/build/vignette.rds
aop/DESCRIPTION
aop/man
aop/man/internal_model_fits.Rd aop/man/pod_envelope_analysis.Rd aop/man/convert_aop_to_graph.Rd aop/man/pod_slope_analysis.Rd aop/man/bmr-class.Rd aop/man/aop_backdoor.Rd aop/man/aop_cytoscape-class.Rd aop/man/oxybenzone.Rd aop/man/calculate_confidence_and_median.Rd aop/man/plot_metaregression_spaghetti_plot.Rd aop/man/aop_cytoscape-methods.Rd aop/man/slope_pod_analysis.Rd aop/man/convert_cytoscape_to_aop.Rd aop/man/bootstrap_metaregression.Rd aop/man/plot_slope_analysis.Rd aop/man/plot_metaregression_confidence_envelope.Rd

Questions? Problems? Suggestions? or email at ian@mutexlabs.com.

All documentation is copyright its authors; we didn't write any of that.